Clinical Trial Update: A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating nivolumab and relatlimab in combination with bevacizumab for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: COMPLETED